Dose scheduling and pharmacokinetic (PK) study of trastuzumab in patients (pts) with HER2/neu overexpressing breast cancer?A. Felici, F. Cognetti, G. Ferretti et al.|Journal of Clinical Oncology|2007Cited by 3
Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.Paola Papaldo, F. Cognetti, Giulio Metro et al.|Journal of Clinical Oncology|2010Cited by 0
Fulvestrant administered in two different schedules: Pharmacokinetics, biological markers, and activity.A. Felici, Paola Papaldo, Francesco Cognetti et al.|Journal of Clinical Oncology|2011Cited by 0